Table 2

IC50 of cisplatin and DACH-acetato-Pt in wild-type, mutant, and null p53 ovarian cancer cell lines following continuous or 2-h drug exposures

Cell lineContinuous drug exposure2-h drug exposure
CisplatinDACH-acetato-PtCisplatin/DACH-acetato-Pt ratioCisplatinDACH-acetato-PtCisplatin/DACH-acetato-Pt ratio
Wild-type p53
 OVCA-4202.93 ± 0.18a1.49 ± 0.241.9721.2 ± 1.738.39 ± 0.812.53
 OVCA-4294.10 ± 0.630.79 ± 0.105.1924.8 ± 1.675.61 ± 0.754.42
 OVCA-4339.90 ± 2.861.07 ± 0.339.25103.3 ± 9.709.83 ± 1.3910.5
 OVCAR-108.90 ± 1.770.17 ± 0.0152.4109.5 ± 12.26.32 ± 0.5317.3
 HEY2.78 ± 0.230.45 ± 0.056.1829.9 ± 2.148.08 ± 0.983.70
Mutant or null p53
 OVCA-4322.03 ± 0.2511.3 ± 2.080.1816.1 ± 1.9173.2 ± 7.330.22
 OVCAR-31.22 ± 0.332.65 ± 0.760.466.64 ± 0.9823.5 ± 2.830.28
 OCC13.30 ± 0.929.85 ± 3.650.3419.3 ± 2.21108.1 ± 10.30.18
 SKOV-31.32 ± 0.173.18 ± 0.570.428.87 ± 1.1044.2 ± 3.810.20
  • a Mean ± SE; n = 3–5.